VPRIV® (velaglucerase alfa) for injection is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Support Programs

When you're prescribed VPRIV, and throughout your journey, you will be supported all the way. For patients enrolled in Takeda Patient Support, Takeda offers a range of support to help answer questions.

Patient Support logo

TAKEDA PATIENT SUPPORT

Takeda Patient Support is a product support program for people who have been prescribed VPRIV. After you and your physician choose a treatment path, Takeda Patient Support is here for you with a range of personalized services for your treatment journey — even when you need to travel away from home.

Our support specialists are here to address your questions and concerns, and help get you the answers, resources, and tools you need. Some of the ways we can help include:

Blue dollar symbol icon

Financial Assistance Options

Copay assistance for those who are eligible,* as well as assistance with navigating complex reimbursement and insurance issues

Blue calendar icon

Coordinate with Site of Care

Coordination between your specialty pharmacy and your site of care, even if you are traveling out of town or relocating

Blue ipad icon

Resources and Education

Helping you find information, education, and community resources about your condition on Gaucher disease

Blue icon with house and two arrows pointing left and right

Assistance During Life Transitions

Assistance during life transitions like relocation, moving to college, or changing jobs

To learn more about Takeda Patient Support, visit: TakedaPatientSupport.com

*To be eligible, the patient must be enrolled in Takeda Patient Support, and have commercial insurance. Other terms and conditions apply. Call for more details.

Want to Connect

Want to connect?

Our support specialists are never more than a tap or a call away — 1-866-888-0660, Monday through Friday, 8:30 am to 8:00 pm ET.

If English is not your preferred language, let your support specialist know. The team can communicate over the phone in a variety of languages — including Spanish, Yiddish, and more — using a translation service.

Want to get started in Takeda Patient Support? Here’s what to do:

1. Work with your healthcare provider to complete the Start Form for your prescribed Takeda treatment.

2. Sign the Patient Authorization section of the Start Form.

Takeda Patient Support will confirm your eligibility. Your dedicated support specialist will call you.

Bubble Top Left
QuickStart logo

QuickStart can help streamline your VPRIV treatment initiation.

When starting VPRIV—whether you’re new to enzyme replacement therapy (ERT) or just switching from another treatment—there may be some administrative hurdles with insurance. One of the most commonly encountered issues that has the potential to delay the start of your treatment is called a prior authorization (PA).

A prior authorization is when your insurance company requires your doctor to fill out some additional paperwork before your prescription is processed. This can delay you from starting treatment while your paperwork is being evaluated and processed.

QuickStart allows eligible patients to receive their infusion while the prior authorization is still being reviewed. You could receive up to two free doses of VPRIV, if eligible and prescribed by your doctor.

Fill in a QuickStart Form with your Doctor or visit TakedaPatientSupport.com to learn more. If you are enrolled with Takeda Patient Support our support specialists can help you answer any questions you may have on the QuickStart program.*

*Additional terms and conditions apply.

Bubble Bottom Right
PreppedAhead program icon

What many patients don’t always expect when starting an ERT is that in addition to infusion time, there is usually some time associated with a site of care’s infusion preparation.

PreppedAhead is a program that provides you with the option of having your site of care prepare your treatment before you arrive—so you don’t have to wait as long before your infusion begins.

This service is only available to patients enrolled in Takeda Patient Support at sites of care that are enrolled in the PreppedAhead program. Talk to Takeda Patient Support about PreppedAhead today.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat. VPRIV should be administered under the supervision of a healthcare professional. Appropriate medical support should be available when VPRIV is administered.

Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.

If anaphylactic or other acute reactions occur, seek immediate medical care. Your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.

The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.

Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.

The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.

As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 (2%) patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. One additional patient developed antibodies to VPRIV during an extension study. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.

For additional safety information, please click here for Full Prescribing Information including WARNING for Risk of Anaphylaxis, and discuss with your doctor
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, contact Takeda at 1-877-TAKEDA-7 (1-877-825-3327), or by email at medinfous@takeda.com